Nanjing Chia Tai Tianqing will win the first imitation of 4 blockbuster new products have been approved

A few days ago, the official website of the State Food and Drug Administration showed that Nanjing Zhengda Tianqing entered the administrative examination and approval stage with the imitation of three types of safinamide mesylate tablets, which is expected to fill the gap in the domestic market
.
According to data from Mi Nei.
com, since 2021, Nanjing Chia Tai Tianqing has approved 4 products for listing
.
Source: The official website of the State Drug Administration.
Safinamide (Safinamide) is a highly selective and reversible third-generation monoamine oxidase B (MAO-B) inhibitor with dual dopaminergic and non-dopaminergic mechanisms
.
The original research product was first approved by the FDA in March 2017.
It is the first new chemical entity approved for the treatment of Parkinson's disease in the United States in the past 10 years
.
At present, the original research products have not been approved for import.
Nanjing Chia Tai Tianqing and Yangtze River have submitted listing applications in three types of imitations.
Among them, Nanjing Chia Tai Tianqing's products are the first to enter the administrative approval stage and are expected to win the first imitation
.
According to Meinenet data, in 2020, the market size of China's urban public hospitals , county-level public hospitals, urban community centers, township health centers (referred to as Chinese public medical institutions) and China's urban physical pharmacies will exceed 2.
7 billion yuan.
A year-on-year increase of 14.
37%
.
In China’s public medical institutions, the TOP5 anti-Parkinson’s disease drugs are Pramipexole, Dopasizide, Entacapone, Trihexyphenidyl, and Piribedil, with sales exceeding 100 million yuan; At the end of physical pharmacies in cities in China, the TOP5 anti-Parkinson's disease drugs are dopasizide, pramipexole, piribedil, entacapone, and rasagiline
.
2020 China's urban physical pharmacies terminal anti-Parkinson's disease drugs TOP5 Source: Meinnet.
com.
Chinese urban physical pharmacies terminal competition pattern.
If Nanjing Zhengda Tianqing's safinamide mesylate tablets are successfully approved, it will be a domestic anti-Parkinsonian drug of more than 2.
7 billion Parkinson's disease drug market injects new vitality
.
From 2021 to the present, Nanjing Chia Tai Tianqing's products have been approved.
Source: Meinenet.
com MED2.
0 Chinese drug review database.
Meinenet.
com data shows that from 2021 until now, Nanjing Chia Tai Tianqing has approved 4 generic drugs for marketing and deemed to have been reviewed.
Among them, aprepitant capsules are the third domestic manufacturer, and amlodipine, atorvastatin calcium tablets and tolvaptan tablets are the second domestic manufacturer
.
Source: Meinenet database, official website of the State Food and Drug Administration.
Note: China's urban entity pharmacy terminal competition pattern database covers entity pharmacies in 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors the entire category.
Edition city entity pharmacy database
.
The above sales are calculated based on the average retail price of the product at the terminal
.
Statistics are as of August 13, if there are any omissions, please correct me!